TEST:

SHIELDING™

Herein, we report a comprehensive error suppressing approach for removing background artifacts by fixed MRD panel, allowing an enhanced MRD detection in post-surgical lung cancer patients. Our approach, which accurately identified ctDNA status at a cost-effective rate, outperformed other fixed panels while showing comparable performance with personalized panels. Furthermore, our method can be utilized under tumor naïve scenarios when personalized panels are unfeasible in the absence of tumor information.

Our method stands as an ultra-sensitive tool for identifying colorectal patients at high risk of recurrence. By employing an adaptive noise cancellation algorithm, our fixed panel approach demonstrates superiority over existing fixed panels in accuracy and proves to be a cost-effective alternative to personalized panels. Significantly, it extends potential clinical utilization towards tumor-naïve patients, which is not feasible for personalized panels.

"Geneseeq Technology Inc. has announced the initiation of the MOTION study in collaboration with ten clinical sites to evaluate the performance of Geneseeq’s minimal residual disease test SHIELDING™ in patients with operable early-stage non-small cell lung cancer (NSCLC)."

"Geneseeq Technology Inc. announced that Geneseeq’s multi-cancer minimal residual disease detection (MRD) and multi-cancer early detection (MCED) kits were both CE Marked for liquid biopsy use in solid tumor patients...The MRD detection kit (Shielding™) employs ultra-deep sequencing technology ATG-SEQ™ to detect low amounts of circulating tumor DNA (ctDNA) in the peripheral blood post-surgical intervention...For early cancer detection, the in vitro diagnostic kit uses highly sensitive next-generation sequencing-based technology MERCURY™ to assess multi-omics features of circulating free DNA (cfDNA) and detect tumorigenesis in health population."

"In the CALIBRATE(monitoring post-surgery CAncer recurrence by ctDNA LIquid Biopsy RATing)-NSCLC program, Geneseeq and the Chinese Academy of Medical Sciences published a recent prospective study in Nature Communications, employing SHIELDING, Geneseeq’s newly launched MRD product to dynamically monitor residual circulating tumor DNA (ctDNA) in non-small cell lung cancer (NSCLC) patients who received surgery with/without adjuvant chemotherapy (ACT). The researchers demonstrated pioneering works of using residual ctDNA to guide ACT and applying cutting-edge mathematical models to predict recurrence risk."